

初示報告
Initial Report

Aoi Seicha Co., Ltd.

REPORT NO : FA/2016/50790

Date : 2016/05/12




The following sample(s) was/were submitted and identified by/on behalf of client as:

<u>Type of Product:</u>	Organic Matcha ODE
<u>Sample condition</u>	Please refer to the photos for sample shown at the last page of this report
<u>Item No.:</u>	TW16-015
<u>Lot. No.:</u>	AODE0406F
<u>Applicant :</u>	Taiwan Tea Manufacturers' Association
<u>Manufacturer/Vendor :</u>	Aoi Seicha Co., Ltd.
<u>Manufacture Date :</u>	—
<u>Expiry Date :</u>	—
<u>Country of Origin :</u>	Japan
<u>Date of Sample Received :</u>	2016/05/06
<u>Date of Testing :</u>	2016/05/06
<u>Test Requested :</u>	Determination of the pesticides
<u>Test Method :</u>	#According to MOHW Food No. 1031900615 Method of Test for Pesticide Residues in Food-Multi-Residue Analysis(5). Analysis were performed by GC/MS/MS and LC/MS/MS.

Test Results : **This sample is tested 310 pesticides .This sample is non-detected in 310 pesticides listed in the appendix**

- Note : 1. The test report merely reflects the test results of the consigned matters of the client and is not a certification of the legitimacy of the related products.
2. The report is in vain if it is partly reproduced or used.
3. The test result over LOQ is summarized in the table. All test items and LOQ are listed in appendix.
4. If the testing item belongs to quantitative analysis then this column describes Limit of Quantification(LOQ).
5. According to the remark of FDA Ministry of Health and Welfare of Taiwan's most updated announcement on the test methods:
This test method is not suitable for testing Benfuracarb and Pymetrozine inside tealeaf substrate.
6. The testing method having been accredited by MOHW are added with a mark "#".

- END -


Enoch Huang, Manager
Signed for and on behalf of
SGS Taiwan Ltd.

Special Remark :

This initial report is issued for notification only, detailed results are governed by the final test report.

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

初示報告

Initial Report

Appendix

REPORT NO: FA/2016/50790

Date : 2016/05/12



Test items & LOQ List : unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
1.	3-keto Carbofuran	16709-30-1	0.05	41.	Bupirimate	41483-43-6	0.05
2.	3-OH carbofuran	16655-82-6	0.05	42.	Buprofezin	69327-76-0	0.05
3.	Abamectin	71751-41-2	0.05	43.	Butachlor	23184-66-9	0.05
4.	Acephate	30560-19-1	0.05	44.	Butocarboxim	34681-10-2	0.05
5.	Acetamidrid	135410-20-7	0.05	45.	Butralin	33629-47-9	0.05
6.	Acetochlor	34256-82-1	0.1	46.	Carbaryl	63-25-2	0.05
7.	Acrinathrin	101007-06-1	0.05	47.	Carbendazim	10605-21-7	0.05
8.	Alachlor	15972-60-8	0.05	48.	Carbofuran	1563-66-2	0.05
9.	Aldicarb	116-06-3	0.02	49.	Carbophenothion	786-19-6	0.05
10.	Aldicarb sulfone	1646-88-4	0.02	50.	Carbosulfan	55285-14-8	0.05
11.	Aldicarb sulfoxide	1646-87-3	0.02	51.	Carpropamid	104030-54-8	0.05
12.	Aldrin	309-00-2	0.03	52.	Chinomethionat	2439-01-2	0.05
13.	Allethrin	584-79-2	0.1	53.	Chlorantraniliprole	500008-45-7	0.05
14.	Alloxydim(sodium)	55635-13-7	0.05	54.	cis-Chlordane	5103-71-9	0.05
15.	Alphacypermethrin	67375-30-8	0.5	55.	trans-Chlordane	5103-74-2	0.05
16.	Ametryn	834-12-8	0.05	56.	Chlorfenapyr	122453-73-0	0.1
17.	Amisulbrom	348635-87-0	0.05	57.	Chlorfluazuron	71422-67-8	0.05
18.	Atrazine	1912-24-9	0.05	58.	Chloropropylate	5836-10-2	0.02
19.	Azinphos-methyl	86-50-0	0.1	59.	Chlorothalonil	1897-45-6	0.1
20.	Azoxystrobin	131860-33-8	0.05	60.	Chlorpropham	101-21-3	0.05
21.	Benalaxyl	71626-11-4	0.05	61.	Chlorpyrifos	2921-88-2	0.05
22.	Bendiocarb	22781-23-3	0.05	62.	Chlorpyrifos-methyl	5598-13-0	0.05
23.	Benfluralin	1861-40-1	0.05	63.	Chlorthal-dimethyl	1861-32-1	0.05
24.	Benfuracarb	82560-54-1	Note 5.	64.	Chlozolate	84332-86-5	0.05
25.	Bensulfuron-methyl	83055-99-6	0.05	65.	Chromafenozide	143807-66-3	0.05
26.	Bentazone	25057-89-0	0.05	66.	Cinosulfuron	94593-91-6	0.05
27.	Benthiazole	21564-17-0	0.05	67.	Clofentezine	74115-24-5	0.05
28.	α-BHC	319-84-6	0.03	68.	Clomazone	81777-89-1	0.05
29.	β-BHC	319-85-7	0.05	69.	Clomeprop	84496-56-0	0.05
30.	δ-BHC	319-86-8	0.05	70.	Clothianidin	210880-92-5	0.05
31.	Bifenazate	149877-41-8	0.05	71.	Cyanofenphos	13067-93-1	0.05
32.	Bifenox	42576-02-3	0.05	72.	Cyazofamid	120116-88-3	0.05
33.	Bifenthrin	82657-04-3	0.05	73.	Cyclosulfamuron	136849-15-5	0.05
34.	Bitertanol	55179-31-2	0.05	74.	Cyflumetofen	400882-07-7	0.05
35.	Boscalid	188425-85-6	0.05	75.	Cyfluthrin	68359-37-5	0.05
36.	Bromacil	314-40-9	0.05	76.	Cyhalofop-butyl	122008-85-9	0.05
37.	Bromophos-ethyl	4824-78-6	0.05	77.	Cyhalothrin	91465-08-6	0.05
38.	Bromophos-methyl	2104-96-3	0.1	78.	Cymoxanil	57966-95-7	0.05
39.	Bromopropylate	18181-80-1	0.05	79.	Cypermethrin	52315-07-8	0.5
40.	Bromuconazole	116255-48-2	0.05	80.	Cyproconazole	94361-06-5	0.05

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

初示報告
Initial Report

Appendix

REPORT NO: FA/2016/50790

Date : 2016/05/12



Test items & LOQ List :

unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
81.	Cyprodinil	121552-61-2	0.05	121.	Etofenprox	80844-07-1	0.05
82.	o,p'-DDD	53-19-0	0.02	122.	Etoxazole	153233-91-1	0.05
83.	o,p'-DDE	3424-82-6	0.02	123.	Etrimfos	38260-54-7	0.05
84.	o,p'-DDT	789-02-6	0.02	124.	Famoxadone	131807-57-3	0.05
85.	p,p'-DDD	72-54-8	0.02	125.	Fenamiphos	22224-92-6	0.05
86.	p,p'-DDE	72-55-9	0.02	126.	Fenarimol	60168-88-9	0.05
87.	p,p'-DDT	50-29-3	0.02	127.	Fenazaquin	120928-09-8	0.05
88.	Deltamethrin	52918-63-5	0.05	128.	Fenbuconazole	114369-43-6	0.05
89.	Demeton-S-methyl	919-86-8	0.05	129.	Fenbutatin-oxide	13356-08-6	0.05
90.	Diazinon	333-41-5	0.05	130.	Fenhexamid	126833-17-8	0.05
91.	Dichlorvos	62-73-7	0.05	131.	Fenitrothion	122-14-5	0.05
92.	Dicloran	99-30-9	0.05	132.	Fenobucarb	3766-81-2	0.05
93.	Dicofol&DCBP	115-32-2	0.05	133.	Fenothiocarb	62850-32-2	0.05
94.	Dicrotophos	141-66-2	0.05	134.	Fenoxaprop-ethyl	66441-23-4	0.05
95.	Dieldrin	60-57-1	0.05	135.	Fenoxycarb	79127-80-3	0.05
96.	Difenoconazole	119446-68-3	0.05	136.	Fenpropathrin	39515-41-8	0.05
97.	Diflubenzuron	35367-38-5	0.05	137.	Fenpropimorph	67564-91-4	0.05
98.	Dimethenamid	87674-68-8	0.05	138.	Fenpyroximate	134098-61-6	0.05
99.	Dimethoate	60-51-5	0.05	139.	Fensulfothion	115-90-2	0.25
100.	Dimethomorph	110488-70-5	0.05	140.	Fenthion	55-38-9	0.05
101.	Diniconazole	83657-24-3	0.05	141.	Fenvalerate	51630-58-1	0.05
102.	Dinitramine	29091-05-2	0.05	142.	Fipronil	120068-37-3	0.002
103.	Dinotefuran	165252-70-0	0.05	143.	Flazasulfuron	104040-78-0	0.05
104.	Diphenamid	957-51-7	0.05	144.	Flonicamid	158062-67-0	0.05
105.	Disulfoton	298-04-4	0.05	145.	Fluazifop-P-butyl	69806-50-4	0.05
106.	Ditalimfos	5131-24-8	0.03	146.	Fluazinam	79622-59-6	0.05
107.	Diuron	330-54-1	0.05	147.	Flucythrinate	70124-77-5	0.05
108.	Dymron	42609-52-9	0.05	148.	Fludioxonil	131341-86-1	0.06
109.	Edifenphos	17109-49-8	0.05	149.	Flufenoxuron	101463-69-8	0.05
110.	α-Endosulfan	959-98-8	0.05	150.	Fluopicolide	239110-15-7	0.05
111.	β-Endosulfan	33213-65-9	0.1	151.	Flusilazole	85509-19-9	0.05
112.	Endosulfan sulfate	1031-07-8	0.1	152.	Flutolanil	66332-96-5	0.05
113.	Endrin	72-20-8	0.05	153.	Flutriafol	76674-21-0	0.05
114.	EPN	2104-64-5	0.03	154.	Fluvalinate	102851-06-9	0.05
115.	Epoxiconazole	133855-98-8	0.05	155.	Fonofos	944-22-9	0.05
116.	Esfenvalerate	66230-04-4	0.05	156.	Formetanate	23422-53-9	0.05
117.	Ethion	563-12-2	0.05	157.	Formothion	2540-82-1	0.05
118.	Ethiprole	181587-01-9	0.05	158.	Fthalide	27355-22-2	0.05
119.	Ethirimol	23947-60-6	0.05	159.	Furametpyr	123572-88-3	0.05
120.	Ethoprophos	13194-48-4	0.05	160.	Halfenprox	111872-58-3	0.05

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

初示報告
Initial Report

Appendix

REPORT NO: FA/2016/50790

Date : 2016/05/12



Test items & LOQ List :

unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
161.	Haloxypop-methyl	69806-40-2	0.05	201.	Methyl pentachlorophenyl sulfide	1825-19-0	0.02
162.	Heptachlor	76-44-8	0.05	202.	Metobromuron	3060-89-7	0.05
163.	Heptachlor epoxide	1024-57-3	0.05	203.	Metolachlor	51218-45-2	0.05
164.	Heptenophos	23560-59-0	0.05	204.	Metolcarb	1129-41-5	0.05
165.	Hexaconazole	79983-71-4	0.05	205.	Metrafenone	220899-03-6	0.05
166.	Hexaflumuron	86479-06-3	0.1	206.	Metribuzin	21087-64-9	0.05
167.	Hexazinone	51235-04-2	0.05	207.	Mevinphos	7786-34-7	0.2
168.	Hexythiazox	78587-05-0	0.05	208.	Mirex	2385-85-5	0.05
169.	Imazalil	35554-44-0	0.05	209.	Molinate	2212-67-1	0.25
170.	Imibenconazole	86598-92-7	0.25	210.	Monocrotophos	6923-22-4	0.05
171.	Imidacloprid	138261-41-3	0.05	211.	Myclobutanil	88671-89-0	0.05
172.	Indoxacarb	144171-61-9	0.01	212.	Napropamide	15299-99-7	0.05
173.	Iprobenfos	26087-47-8	0.05	213.	Norflurazon	27314-13-2	0.05
174.	Iprodione	36734-19-7	0.05	214.	Novaluron	116714-46-6	0.05
175.	Isazofos	42509-80-8	0.05	215.	Nuarimol	63284-71-9	0.05
176.	Isofenphos	25311-71-1	0.05	216.	Omethoate	1113-02-6	0.05
177.	Isoprocab	2631-40-5	0.05	217.	Oxadiazon	19666-30-9	0.05
178.	Isoprothiolane	50512-35-1	0.05	218.	Oxadixyl	77732-09-3	0.05
179.	Isouron	55861-78-4	0.05	219.	Oxamyl	23135-22-0	0.05
180.	Isoxathion	18854-01-8	0.1	220.	Oxycarboxin	5259-88-1	0.05
181.	Kresoxim-methyl	143390-89-0	0.05	221.	Oxyfluorfen	42874-03-3	0.05
182.	Lindane	58-89-9	0.05	222.	Paclobutrazol	76738-62-0	0.05
183.	Linuron	330-55-2	0.05	223.	Parathion	56-38-2	0.05
184.	Lufenuron	103055-07-8	0.05	224.	Parathion-methyl	298-00-0	0.05
185.	Malathion	121-75-5	0.05	225.	Penconazole	66246-88-6	0.05
186.	Mecarbam	2595-54-2	0.05	226.	Pencycuron	66063-05-6	0.05
187.	Mefenacet	73250-68-7	0.05	227.	Pendimethalin	40487-42-1	0.05
188.	Mepanipyrim	110235-47-7	0.05	228.	Penoxsulam	219714-96-2	0.05
189.	Mephosfolan	950-10-7	0.05	229.	Pentachloroaniline	527-20-8	0.02
190.	Mepronil	55814-41-0	0.05	230.	Permethrin	52645-53-1	0.05
191.	Metaflumizon	139968-49-3	0.05	231.	Phenthoate	2597-03-7	0.05
192.	Metalaxyl	57837-19-1	0.05	232.	Phorate	298-02-2	0.05
193.	Metazachlor	67129-08-2	0.05	233.	Phosalone	2310-17-0	0.05
194.	Metconazole	125116-23-6	0.05	234.	Phosmet	732-11-6	0.05
195.	Methacrifos	62610-77-9	0.1	235.	Phosphamidon	13171-21-6	0.05
196.	Methamidophos	10265-92-6	0.05	236.	Phoxim	14816-18-3	0.05
197.	Methidathion	950-37-8	0.05	237.	Pirimicarb	23103-98-2	0.05
198.	Methiocarb	2032-65-7	0.05	238.	Pirimiphos-ethyl	23505-41-1	0.05
199.	Methomyl	16752-77-5	0.05	239.	Pirimiphos-methyl	29232-93-7	0.05
200.	Methoxyfenozide	161050-58-4	0.05	240.	Pretilachlor	51218-49-6	0.25

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

初 示 報 告

Initial Report

Appendix

REPORT NO: FA/2016/50790

Date : 2016/05/12



Test items & LOQ List : unit : ppm(mg/kg)

NO.	Test Item	CAS NO.	LOQ	NO.	Test Item	CAS NO.	LOQ
241.	Prochloraz	67747-09-5	0.05	276.	Spiroclorfen	148477-71-8	0.05
242.	Procymidone	32809-16-8	0.05	277.	Spirotetramat	203313-25-1	0.05
243.	Profenophos	41198-08-7	0.05	278.	Tebuconazole	107534-96-3	0.05
244.	Promecarb	2631-37-0	0.02	279.	Tebuconazole	112410-23-8	0.05
245.	Prometryn	7287-19-6	0.05	280.	Tebuconazole	119168-77-3	0.05
246.	Propamocarb hydrochloride	25606-41-1	0.05	281.	Teflubenzuron	83121-18-0	0.05
247.	Propanil	709-98-8	0.05	282.	Tepaloxymid	149979-41-9	0.05
248.	Propaphos	7292-16-2	0.05	283.	Terbufos	13071-79-9	0.05
249.	Propargite	2312-35-8	0.05	284.	Tetraconazole	112281-77-3	0.05
250.	Propiconazole	60207-90-1	0.05	285.	Tetradifon	116-29-0	0.05
251.	Propoxur	114-26-1	0.05	286.	Tetramethrin	7696-12-0	0.05
252.	Prothiofos	34643-46-4	0.05	287.	Thenylchlor	96491-05-3	0.05
253.	Pymetrozine	123312-89-0	Note 5.	288.	Thiabendazole	148-79-8	0.05
254.	Pyraclofos	77458-01-6	0.05	289.	Thiacloprid	111988-49-9	0.05
255.	Pyraclostrobin	175013-18-0	0.05	290.	Thiamethoxam	153719-23-4	0.05
256.	Pyrazophos	13457-18-6	0.05	291.	Thifluzamide	130000-40-7	0.05
257.	Pyridaben	96489-71-3	0.05	292.	Thiobencarb	28249-77-6	0.05
258.	Pyridaphenthion	119-12-0	0.05	293.	Thiodicarb	59669-26-0	0.05
259.	Pyridate	55512-33-9	0.06	294.	Tolclofos-methyl	57018-04-9	0.05
260.	Pyrifenoxy	88283-41-4	0.05	295.	Tolfenpyrad	129558-76-5	0.05
261.	Pyrimethanil	53112-28-0	0.05	296.	Triadimefon	43121-43-3	0.05
262.	Pyrimidifen	105779-78-0	0.05	297.	Triadimenol	55219-65-3	0.05
263.	Pyriproxyfen	95737-68-1	0.05	298.	Triazophos	24017-47-8	0.05
264.	Pyroquilon	57369-32-1	0.05	299.	Trichlorfon	52-68-6	0.05
265.	Quinalphos	13593-03-8	0.05	300.	Tricyclazole	41814-78-2	0.05
266.	Quinoxifen	124495-18-7	0.05	301.	Tridiphenyl	58138-08-2	0.05
267.	Quintozene(PCNB)	82-68-8	0.02	302.	Trifloxystrobin	141517-21-7	0.05
268.	Quinalofop-ethyl	76578-14-8	0.05	303.	Triflumizole	99387-89-0	0.05
269.	Salithion	3811-49-2	0.03	304.	Trifluralin	1582-09-8	0.04
270.	Silafluofen	105024-66-6	0.05	305.	Triforine	26644-46-2	0.05
271.	Simazine	122-34-9	0.05	306.	Vamidithion	2275-23-2	0.05
272.	Spinetoram J	187166-40-1	0.05	307.	Vinclozolin	50471-44-8	0.05
273.	Spinetoram L	187166-40-1	0.05	308.	XMC	2655-14-3	0.05
274.	Spinosad A	168316-95-8	0.05	309.	Xylcarb	2425-10-7	0.05
275.	Spinosad D	168316-95-8	0.05	310.	Zoxamide	156052-68-5	0.05

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Aoi Seicha Co., Ltd.

初示報告
Initial Report


REPORT NO : FA/2016/50790

Date : 2016/05/12




Sample Photo

FA/2016/50790



FA/2016/50790



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.